Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease

AIMS: Hyperkalaemia risk precludes optimal renin–angiotensin–aldosterone system inhibitor use in patients with heart failure (HF), particularly those with chronic kidney disease (CKD). Patiromer is a sodium‐free, non‐absorbed potassium (K(+))‐binding polymer approved for the treatment of hyperkalaem...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ESC Heart Fail
Main Authors: Pitt, Bertram, Bushinsky, David A., Kitzman, Dalane W., Ruschitzka, Frank, Metra, Marco, Filippatos, Gerasimos, Rossignol, Patrick, Du Mond, Charles, Garza, Dahlia, Berman, Lance, Lainscak, Mitja
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5933966/
https://ncbi.nlm.nih.gov/pubmed/29369537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12265
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados